Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

IKKb-matured RNA-loaded autologous dendritic cells DCIKKb

A cancer vaccine consisting of autologous, monocyte-derived dendritic cells (DCs) that are matured with tumor necrosis factor-alpha (TNF-alpha), interleukin-1 (IL-1) beta, IL-6, prostaglandin E2 (PGE2) and IkB kinase b (IKKb), and loaded by electroporation with autologous total tumor RNA (TTRNA), RNA coding for tumor-associated antigens (TAAs) that may include gp100, tyrosinase, PRAME, MAGE-A3 and/or IDO, and RNA coding for driver mutations that may include GNAQ/GNA11Q209, R183, SF3B1R625, CYSLTR2L129Q and/or PLCB4D630, with potential immunostimulatory and antineoplastic activities. Upon administration, IKKb-matured, RNA-loaded autologous DCs DCIKKb may elicit a highly specific cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the TAAs and driver mutations encoded by the loaded RNA.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:IKKb-matured RNA-loaded autologous DCs DCIKKb
Abbreviation:DCIKKb
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search